<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Palovarotene: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Palovarotene: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Palovarotene: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_pediatric" data-topicid="139381" href="/d/html/139381.html" rel="external">see "Palovarotene: Pediatric drug information"</a> and <a class="drug drug_patient" data-topicid="139382" href="/d/html/139382.html" rel="external">see "Palovarotene: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block black-box-warn drugH1Div" id="F58579050"><span class="drugH1">ALERT: US Boxed Warning</span>
<div class="collapsible">
<span class="collapsible-title">Embryo-fetal toxicity:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Palovarotene is contraindicated in pregnancy. Palovarotene may cause fetal harm. Because of the risk of teratogenicity and to minimize fetal exposure, palovarotene is to be administered only if conditions for pregnancy prevention are met.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Premature epiphyseal closure:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Premature epiphyseal closure occurs in growing pediatric patients treated with palovarotene, close monitoring is recommended.</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F58610666"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Sohonos</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F57875169"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Sohonos</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F57119280"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Retinoic Acid Receptor Gamma Agonist</li></ul></div>
<div class="block doa drugH1Div" id="F57216275"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="35e4ef4c-8ac5-4d40-bbb9-8ee943fd0050">Heterotopic ossification</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Heterotopic ossification:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Chronic regimen: <b>Oral:</b> 5 mg once daily.</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note:</b> Discontinue chronic treatment at the initiation of flare-up treatment and reinitiate treatment after completion of flare-up treatment.</p>
<p style="text-indent:-2em;margin-left:4em;">Flare-up regimen: <b>Oral:</b> 20 mg once daily for 4 weeks followed by 10 mg once daily for 8 weeks for a total of 12 weeks; continue treatment even if symptoms resolve earlier. If flare-up symptoms have not resolved at the end of the 12-week period, treatment may be extended in 4-week intervals with 10 mg once daily until flare-up symptoms resolve. If new flare-up symptoms occur after the 5 mg daily dosing is resumed, flare-up dosing may be restarted.</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note:</b> Initiate flare-up treatment at the onset of the first symptom or high-risk traumatic event likely to lead to a flare-up. If an additional flare-up (a new flare-up location or marked worsening of the original flare-up) occurs at any time during the flare-up treatment, the 12-week flare-up regimen should be restarted.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Missed dose:</b> Take missed dose as soon as possible on the same day; skip dose if missed by &gt;6 hours. Do not double doses to compensate for a missed dose.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F57216277"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Mild to moderate impairment (CrCl ≥30 mL/minute): No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:2em;">Severe impairment (CrCl 15 to 29 mL/minute): Use is not recommended (has not been studied).</p></div>
<div class="block doha drugH1Div" id="F57216278"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Mild impairment (Child-Turcotte-Pugh class A): No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:2em;">Moderate to severe impairment (Child-Turcotte-Pugh class B or C): Use is not recommended (has not been studied).</p></div>
<div class="block dot drugH1Div" id="F57216279"><span class="drugH1">Dosing: Adjustment for Toxicity: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Adverse reactions:</b> In patients experiencing adverse reactions requiring dosage reduction during daily dosing or flare-up dosing, reduce the daily dosage to the next lower dosage at health care providers discretion as in table below. Dosage may be reduced further if adverse reactions do not improve. In patients already receiving the lowest possible tolerated dose, consider temporary or permanently discontinuing therapy. Subsequent flare-up dosing should be initiated at the same reduced dose that was previously tolerated.</p>
<table border="1" frame="border" rules="all" style="margin-left:4em;">
<caption style="text-align:left;">
<b>Dose Reduction for Palovarotene</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
</colgroup><thead valign="top">
<tr>
<th align="left">
<p style="text-indent:0em;">
<b>Dose prescribed</b></p></th>
<th align="left">
<p style="text-indent:0em;">
<b>Reduced dose</b></p></th></tr></thead>
<tbody valign="top">
<tr>
<td align="left">
<p style="text-indent:0em;">20 mg</p></td>
<td align="left">
<p style="text-indent:0em;">15 mg</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">15 mg</p></td>
<td align="left">
<p style="text-indent:0em;">12.5 mg</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">12.5 mg</p></td>
<td align="left">
<p style="text-indent:0em;">10 mg</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">10 mg</p></td>
<td align="left">
<p style="text-indent:0em;">7.5 mg</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">7.5 mg</p></td>
<td align="left">
<p style="text-indent:0em;">5 mg</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">6 mg</p></td>
<td align="left">
<p style="text-indent:0em;">4 mg</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">5 mg</p></td>
<td align="left">
<p style="text-indent:0em;">2.5 mg</p></td></tr></tbody></table></div>
<div class="block doe drugH1Div" id="F57216276"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block dop drugH1Div" id="F57971721"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="139381" href="/d/html/139381.html" rel="external">see "Palovarotene: Pediatric drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="be64e266-9475-4c5c-bbaa-ee70b5e83af1">Heterotopic ossification secondary to fibrodysplasia ossificans progressiva</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Heterotopic ossification secondary to fibrodysplasia ossificans progressiva: Note:</b> Minimum age for use dependent upon patient sex. Dose dependent on phase of disease (chronic or flare-up).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Chronic regimen</i>: Oral:</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note:</b> Discontinue chronic treatment at the initiation of flare-up treatment and reinitiate chronic treatment after completion of flare-up treatment.</p>
<table border="1" frame="border" rules="all" style="margin-left:6em;">
<caption style="text-align:left;">
<b>Chronic Regimen for Palovarotene</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead valign="top">
<tr>
<th align="left">
<p style="text-indent:0em;">Age</p></th>
<th align="left">
<p style="text-indent:0em;">Weight</p></th>
<th align="left">
<p style="text-indent:0em;">Dose</p></th></tr></thead>
<tbody valign="top">
<tr>
<td align="left" rowspan="4">
<p style="text-indent:0em;">Female Children ≥8 years or Male Children ≥10 years and Adolescents &lt;14 years</p></td>
<td align="left">
<p style="text-indent:0em;">10 to &lt;20 kg</p></td>
<td align="left">
<p style="text-indent:0em;">2.5 mg once daily</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">20 to &lt;40 kg</p></td>
<td align="left">
<p style="text-indent:0em;">3 mg once daily</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">40 to &lt;60 kg</p></td>
<td align="left">
<p style="text-indent:0em;">4 mg once daily</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">≥60 kg</p></td>
<td align="left">
<p style="text-indent:0em;">5 mg once daily</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">Adolescents ≥14 years</p></td>
<td align="left">
<p style="text-indent:0em;">All weights</p></td>
<td align="left">
<p style="text-indent:0em;">5 mg once daily</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">
<i>Flare-up regimen: </i>Oral:</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note: </b>Total flare-up treatment duration is 12 weeks; continue treatment even if symptoms resolve earlier. If the patient experiences another flare-up (new location or worsening) during a 12-week flare-up regimen, restart flare-up treatment schedule. If flare-up symptoms not resolved by the end of the 12-week regimen, week 5 to 12 dosing may be extended at 4-week intervals and continued until the flare-up symptoms resolve. If new flare-up symptoms occur after chronic dosing regimen is resumed, flare-up dosing may be restarted.</p>
<table border="1" frame="border" rules="all" style="margin-left:6em;">
<caption style="text-align:left;">
<b>Flare-Up Regimen for Palovarotene</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead valign="top">
<tr>
<th align="left">
<p style="text-indent:0em;">
<b>Age</b></p></th>
<th align="left">
<p style="text-indent:0em;">
<b>Weight</b></p></th>
<th align="left">
<p style="text-indent:0em;">
<b>Initial (Weeks 1 to 4)</b></p></th>
<th align="left">
<p style="text-indent:0em;">
<b>Subsequent (Weeks 5 to 12)</b></p></th></tr></thead>
<tbody valign="top">
<tr>
<td align="left" rowspan="4">
<p style="text-indent:0em;">Female Children ≥8 years or Male Children ≥10 years and Adolescents &lt;14 years</p></td>
<td align="left">
<p style="text-indent:0em;">10 to &lt;20 kg</p></td>
<td align="left">
<p style="text-indent:0em;">10 mg once daily</p></td>
<td align="left">
<p style="text-indent:0em;">5 mg once daily</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">20 to &lt;40 kg</p></td>
<td align="left">
<p style="text-indent:0em;">12.5 mg once daily</p></td>
<td align="left">
<p style="text-indent:0em;">6 mg once daily</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">40 to &lt;60 kg</p></td>
<td align="left">
<p style="text-indent:0em;">15 mg once daily</p></td>
<td align="left">
<p style="text-indent:0em;">7.5 mg once daily</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">≥60 kg</p></td>
<td align="left">
<p style="text-indent:0em;">20 mg once daily</p></td>
<td align="left">
<p style="text-indent:0em;">10 mg once daily</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">Adolescents ≥14 years</p></td>
<td align="left">
<p style="text-indent:0em;">All weights</p></td>
<td align="left">
<p style="text-indent:0em;">20 mg once daily</p></td>
<td align="left">
<p style="text-indent:0em;">10 mg once daily</p></td></tr></tbody></table></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosing adjustment for toxicity:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Female Children ≥8 years or Male Children ≥10 years and Adolescents: Oral:</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note: </b>If intolerable adverse reactions occur during chronic or flare-up regimen, palovarotene doses should be reduced to the next lower dose. If patient is receiving the lowest possible tolerated dose, consider holding dose or discontinuing. Subsequent flare-up dosing should be initiated at last tolerated dose.</p>
<table border="1" frame="border" rules="all" style="margin-left:6em;">
<caption style="text-align:left;">
<b>Palovarotene Dose Reductions</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
</colgroup><thead valign="top">
<tr>
<th align="left">
<p style="text-indent:0em;">
<b>Dose Prescribed</b></p></th>
<th align="left">
<p style="text-indent:0em;">
<b>Reduced Dose</b></p></th></tr></thead>
<tbody valign="top">
<tr>
<td align="left">
<p style="text-indent:0em;">2.5 mg</p></td>
<td align="left">
<p style="text-indent:0em;">1 mg</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">3 mg</p></td>
<td align="left">
<p style="text-indent:0em;">1.5 mg</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">4 mg</p></td>
<td align="left">
<p style="text-indent:0em;">2 mg</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">5 mg</p></td>
<td align="left">
<p style="text-indent:0em;">2.5 mg</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">6 mg</p></td>
<td align="left">
<p style="text-indent:0em;">4 mg</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">7.5 mg</p></td>
<td align="left">
<p style="text-indent:0em;">5 mg</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">10 mg</p></td>
<td align="left">
<p style="text-indent:0em;">7.5 mg</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">12.5 mg</p></td>
<td align="left">
<p style="text-indent:0em;">10 mg</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">15 mg</p></td>
<td align="left">
<p style="text-indent:0em;">12.5 mg</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">20 mg</p></td>
<td align="left">
<p style="text-indent:0em;">15 mg</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F57972149"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Female Children ≥8 years or Male Children ≥10 years and Adolescents: Oral:</p>
<p style="text-indent:-2em;margin-left:4em;">Mild to moderate impairment: No dosage adjustment required. <b>Note: </b>No pharmacokinetic differences were observed in patients with mild or moderate renal impairment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Sohonos.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Sohonos.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Severe impairment: Use is not recommended (has not been studied).</p></div>
<div class="block dohp drugH1Div" id="F57972158"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Female Children ≥8 years or Male Children ≥10 years and Adolescents: Oral:</p>
<p style="text-indent:-2em;margin-left:4em;">Mild impairment: No dosage adjustment required.</p>
<p style="text-indent:-2em;margin-left:4em;">Moderate to severe impairment: Use is not recommended (has not been studied).</p></div>
<div class="block adr drugH1Div" id="F57131770"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Reported adverse reactions are for children, adolescents, and adults.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Peripheral edema (9% to 19%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Alopecia (24% to 30%), cheilitis (38% to 47%), erythema of skin (19% to 32%), exfoliation of skin (15% to 29%), pruritus (34% to 48%), skin irritation (11%), skin rash (28% to 30%), xeroderma (57% to 61%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Nausea (13% to 15%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Hypersensitivity reaction (10% to 20%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Fatigue (5% to 11%; including asthenia), headache (19%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arthralgia (31% to 36%), back pain (11% to 17%), limb pain (28% to 29%), musculoskeletal pain (13% to 14%), myalgia (9% to 12%), premature epiphyseal closure (children and adolescents: 31%)</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Dry eye syndrome (10% to 22%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Hypertriglyceridemia (2% to 4%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Increased serum alanine aminotransferase (2% to 7%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%: Ophthalmic: Night blindness</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Psychiatric disturbance (including anxiety, depression, mood changes, suicidal ideation, suicidal tendencies)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Decreased bone mineral density</p></div>
<div class="block coi drugH1Div" id="F57110434"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity to palovarotene, retinoids, or to any component of the formulation; pregnancy.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling: </i>Breastfeeding; patients who could become pregnant, unless all the conditions for pregnancy prevention are met, or they are not at risk of pregnancy due to physical limitations as assessed by the health care provider.</p></div>
<div class="block war drugH1Div" id="F57216246"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Concerns related to adverse effects:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Bone disorders: Bone toxicity (eg, reductions in bone mass, spontaneous osteoporosis, spontaneous fracture) as well as hyperostotic changes (bone spurs) and ligament/tendon calcification have been reported with retinoid use; may be more common with long-term use or higher doses. Decreased vertebral bone mineral content and bone density and increased risk of radiologically observed vertebral (T4 to L4) fractures have been reported with palovarotene use.</p>
<p style="text-indent:-2em;margin-left:4em;">• Mucocutaneous effects: Mucocutaneous reactions, including dry skin, dry lips, alopecia, pruritus, erythema, rash, skin exfoliation, and dry eye may occur; treatment may further contribute to an increased risk of skin and soft tissue infections (eg, paronychia, decubitus ulcer) due to a decrease in the skin barrier from dry and peeling skin. Dose reduction, more frequent during flare-up dosing, was required in some cases. Prophylactic measures (eg, skin emollients, sunscreen, lip moisturizers, artificial tears) to minimize risk and/or treat the mucocutaneous effects should be considered.</p>
<p style="text-indent:-2em;margin-left:4em;">• Ophthalmic effects: Night blindness has been reported. Night blindness is typically reversible after discontinuation of treatment; use caution when operating vehicles at night. Inform patients to contact health care provider if vision impairment occurs.</p>
<p style="text-indent:-2em;margin-left:4em;">• Photosensitivity: Photosensitivity reactions (eg, exaggerated sunburn reactions [burning, erythema, blistering]) have been associated with the use of retinoids. Avoid excessive exposure to sun or artificial ultraviolet light by wearing protective clothing, sunglasses, and sunscreen.</p>
<p style="text-indent:-2em;margin-left:4em;">• Psychiatric effects: New onset or worsening of existing depression, mood changes, anxiety, and suicidal ideation have been reported with retinoids; risk may be increased in patients with a history of psychiatric illness. Inform patients and caregivers to contact health care provider if psychiatric symptoms occur.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Pediatrics: Skeletal effects: Premature epiphyseal closure and potential adverse effects on growth have been reported in growing children and may be irreversible. In patients that exhibit premature epiphyseal closure or adverse effects on growth based on clinical and radiologic evaluations, assess risks versus benefits of continued treatment versus temporary or permanent discontinuation of palovarotene until the patient reaches epiphyseal closure or skeletal maturity.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Dosage form specific issues:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Lactose: May contain lactose.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Blood donation: Patients should not donate blood during therapy and for 1 week after discontinuing therapy due to the potential risk to the fetus of a pregnant transfusion recipient.</p></div>
<div class="block foc drugH1Div" id="F58610667"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Capsule, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Sohonos: 1 mg</p></div>
<div class="block geq drugH1Div" id="F57875167"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F58659610"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsules</b> (Sohonos Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1 mg (per each): $410.40</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F57875170"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Capsule, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Sohonos: 1 mg</p></div>
<div class="block adm drugH1Div" id="F57216281"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Oral:</b> Administer preferably at the same time every day with food. Capsules may be swallowed whole or entire contents emptied onto 1 teaspoonful (5 mL) of soft food (ie, applesauce, low-fat yogurt, or warm oatmeal) to be used immediately. If opened capsule is not used immediately, it can be taken after a maximum of 1 hour after opening (provided it was maintained at room temperature and not exposed to direct sunlight). Do not administer with grapefruit, grapefruit juice, pomelo, or pomelo juice.</p></div>
<div class="block admp drugH1Div" id="F57972206"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Oral: Administer at the same time every day with food. Capsules may be swallowed whole or entire contents emptied onto 1 teaspoonful (5 mL) of soft food (eg, applesauce, yogurt, pudding, milk, oatmeal, rice cereal, nutritional supplement) to be administered immediately; administer up to a maximum of 1 hour after sprinkling (provided it was maintained at room temperature and not exposed to direct sunlight). Do not administer with grapefruit, grapefruit juice, pomelo, or pomelo juice.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Canadian labeling recommends that individuals handling capsules should wear disposable gloves, use disposable paper towels and a container to collect waste (eg, a resealable bag), and states that caregivers who are pregnant or who plan to become pregnant should not handle capsules.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Missed dose:</i> If &lt;6 hours since scheduled dose, administer missed dose as soon as possible. If ≥6 hours since scheduled dose, skip dose and continue with next scheduled dose. Do not double doses to compensate for a missed dose.</p></div>
<div class="block hazard drugH1Div" id="F57216255"><span class="drugH1">Hazardous Drugs Handling Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">This medication is not on the NIOSH (2016) list; however, it may meet the criteria for a hazardous drug. Palovarotene may cause teratogenicity and has a structural/toxicity profile similar to existing hazardous agents.</p>
<p style="text-indent:-2em;margin-left:2em;">Use appropriate precautions for receiving, handling, storage, preparation, dispensing, transporting, administration, and disposal. Follow NIOSH and USP 800 recommendations <b>and</b> institution-specific policies/procedures for appropriate containment strategy (NIOSH 2016; USP-NF 2020).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note:</b> Facilities may perform risk assessment of some hazardous drugs to determine if appropriate for alternative handling and containment strategies (USP-NF 2020). Refer to institution-specific handling policies/procedures.</p></div>
<div class="block meg drugH1Div" id="F58698729"><span class="drugH1">Medication Guide and/or Vaccine Information Statement (VIS)</span>
<p style="text-indent:0em;display:inline">An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:</p>
<p style="text-indent:-2em;margin-left:4em;">Sohonos: <a href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2023%2F215559s000lbl.pdf%23page%3D20&amp;token=eVL9MIZ2FC3aZxYhalxNt92Yy6bV7w6iILg2GsXl%2FkxwGj1p0mm5nLm08FaEfchnihk%2BYXOCZtUgOE88K2D%2Fqbmezw9GzAD94%2FWoD4VakbVMmbeOmTGnFRmxfNKusNMP&amp;TOPIC_ID=139348" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/215559s000lbl.pdf#page=20</a></p></div>
<div class="block use drugH1Div" id="F57110433"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:0em;display:inline">
<b>Heterotopic ossification:</b> Reduction in the volume of new heterotopic ossification in adults and pediatric patients (females ≥8 years of age; males ≥10 years of age) with fibrodysplasia ossificans progressiva.</p></div>
<div class="block cyt drugH1Div" id="F57149114"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of CYP2C19 (minor), CYP2C8 (minor), CYP3A4 (major); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>
<div class="block dri drugH1Div" id="F57149111"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Aminolevulinic Acid (Systemic): Photosensitizing Agents may enhance the photosensitizing effect of Aminolevulinic Acid (Systemic). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Aminolevulinic Acid (Topical): Photosensitizing Agents may enhance the photosensitizing effect of Aminolevulinic Acid (Topical). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Clofazimine: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inducers (Moderate): May decrease the serum concentration of Palovarotene.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inducers (Strong): May decrease the serum concentration of Palovarotene.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inhibitors (Moderate): May increase the serum concentration of Palovarotene. Management: Avoid concomitant use of palovarotene and moderate CYP3A4 inhibitors when possible. If combined, decrease palovarotene dose by 50% as described in the full interaction monograph. Monitor for palovarotene toxicities when combined.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inhibitors (Strong): May increase the serum concentration of Palovarotene.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fexinidazole: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fusidic Acid (Systemic): May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Grapefruit Juice: May increase the serum concentration of Palovarotene.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methotrexate: Retinoic Acid Derivatives may enhance the hepatotoxic effect of Methotrexate. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methoxsalen (Systemic): Photosensitizing Agents may enhance the photosensitizing effect of Methoxsalen (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Multivitamins/Fluoride (with ADE): May enhance the adverse/toxic effect of Retinoic Acid Derivatives.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Multivitamins/Minerals (with ADEK, Folate, Iron): May enhance the adverse/toxic effect of Retinoic Acid Derivatives.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Multivitamins/Minerals (with AE, No Iron): May enhance the adverse/toxic effect of Retinoic Acid Derivatives.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Porfimer: Photosensitizing Agents may enhance the photosensitizing effect of Porfimer. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Progestins (Contraceptive): Retinoic Acid Derivatives may diminish the therapeutic effect of Progestins (Contraceptive). Retinoic Acid Derivatives may decrease the serum concentration of Progestins (Contraceptive).  Management: Two forms of effective contraception should be used in patients receiving retinoic acid derivatives. Microdosed progesterone-only preparations (ie, minipills that do not contain estrogen) are considered an inadequate method of contraception.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tetracyclines: May enhance the adverse/toxic effect of Retinoic Acid Derivatives. The development of pseudotumor cerebri is of particular concern.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Verteporfin: Photosensitizing Agents may enhance the photosensitizing effect of Verteporfin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vitamin A: May enhance the adverse/toxic effect of Retinoic Acid Derivatives.<i> Risk X: Avoid combination</i></p></div>
<div class="block foi drugH1Div" id="F57216254"><span class="drugH1">Food Interactions</span>
<p style="text-indent:0em;display:inline">Food increases absorption. Grapefruit, grapefruit juice, pomelo, or pomelo juice may interfere with metabolism. Management: Administer with meals; grapefruit, grapefruit juice, pomelo, or pomelo juice should be avoided during therapy.</p></div>
<div class="block rep_considerations drugH1Div" id="F57216239"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">Evaluate pregnancy status and potential for pregnancy prior to use. A negative pregnancy test is required within 1 week prior to the first dose. Pregnancy testing is also required periodically during treatment and 1 month after the last dose of palovarotene in patients who could become pregnant.</p>
<p style="text-indent:0em;margin-top:2em;">Palovarotene is contraindicated in patients who could become pregnant unless they meet all conditions for pregnancy prevention. This includes use of at least 1 highly effective method of contraception (eg, IUD) or 2 effective methods (eg, combined hormonal contraceptive in combination with a barrier method or other method of contraception) during treatment with palovarotene. Effective contraception should be initiated 1 month prior to starting treatment, continued during therapy, and for 1 month after the last palovarotene dose. Patients using the palovarotene flare-up regimen should continue to follow contraception recommendations even during periods when palovarotene is not taken. Patients should understand the teratogenic risk if pregnancy should occur.</p>
<p style="text-indent:0em;margin-top:2em;">Palovarotene is present in semen; concentrations are considered unlikely to effect fetal development.</p></div>
<div class="block pri drugH1Div" id="F57216240"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Based on the mechanism of action and data from animal reproduction studies, in utero exposure to palovarotene may cause severe fetal harm.</p>
<p style="text-indent:0em;margin-top:2em;">Birth defects associated with exposure to retinoids include facial dysmorphia, cleft palate, eye abnormalities, and abnormalities of the CNS, cardiovascular system, musculoskeletal system, and parathyroid hormone deficiencies<i>.</i> All exposed fetuses have the potential to be affected.</p>
<p style="text-indent:0em;margin-top:2em;">Use of palovarotene is contraindicated during pregnancy. If pregnancy occurs during treatment, palovarotene should be discontinued immediately.</p></div>
<div class="block brc drugH1Div" id="F57216241"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">It is not known if palovarotene is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">Due to the potential for serious adverse reactions in the breastfed infant, breastfeeding is not recommended by the manufacturer during therapy and for ≥1 month after the last dose of palovarotene.</p></div>
<div class="block dic drugH1Div" id="F57216280"><span class="drugH1">Dietary Considerations</span>
<p style="text-indent:0em;display:inline">Administer with food. Avoid grapefruit, grapefruit juice, pomelo, or pomelo juice.</p></div>
<div class="block mop drugH1Div" id="F57216285"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:-2em;margin-left:2em;">In growing children, baseline clinical and radiological assessment of skeletal maturity via hand/wrist and knee x-rays, standard growth curves, and pubertal staging. Continued assessment of linear growth and skeletal maturity every 6 to 12 months until patient reaches skeletal maturity or final adult height is recommended. In all patients, periodic radiological assessment of the spine, new or worsening psychiatric symptoms.</p>
<p style="text-indent:-2em;margin-left:2em;">Evaluate pregnancy status and potential for pregnancy (prior to use). A negative pregnancy test is required within 1 week prior to the first dose. Pregnancy testing is also required periodically during treatment, and 1 month after the last dose of palovarotene.</p></div>
<div class="block pha drugH1Div" id="F57216257"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Palovarotene is a retinoic acid receptor gamma (RARγ) selective agonist. RARγ is expressed in chondrogenic cells and chondrocytes operating as an unliganded transcriptional repressor. Through binding to RARγ, palovarotene decreases bone morphogenetic protein signaling and inhibits SMAD1/5/8 signaling. By interfering with these pathways, palovarotene prevents chondrogenesis and heterotopic ossification by enabling normal muscle tissue repair or regeneration to take place, thereby reducing damage to muscle tissue.</p></div>
<div class="block phk drugH1Div" id="F57216258"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Absorption: AUC and C<sub>max</sub> increased ~40% and 16% respectively and T<sub>max</sub> was delayed ~2 hours after a high-fat (50% to 60% of total caloric content of the meal), high-calorie (800 to 1,000 calories, 15% protein, 25% carbohydrate) meal.</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>d/</sub>F: 237 ±90.1 L following administration of 20 mg dose with food.</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: 97.9% to 99.6%.</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Extensively by CYP3A4 and to a minor extent by CYP2C8 and CYP2C19.</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: Mean: 8.7 hours following administration of 20 mg dose for 14 days with standard breakfast (800 to 1,000 calories, 15% protein, 25% carbohydrate, 50% to 60% fat).</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak: Median: 3 to 4 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (3.2%); feces (97.1%).</p></div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference">
                  &lt;800&gt; Hazardous Drugs—Handling in Healthcare Settings. <i>United States Pharmacopeia and National Formulary</i> (USP 43-NF 38). Rockville, MD: United States Pharmacopeia Convention; 2020:74-92.</div>
</li>
<li>
<div class="reference">
                  Sohonos (palovarotene) [prescribing information]. Cambridge, MA: Ipsen Biopharmaceuticals Inc; August 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Sohonos.1">
<a name="Sohonos.1"></a>Sohonos (palovarotene) [product monograph]. Mississauga, Ontario, Canada: Ipsen Biopharmaceuticals Canada Inc; January 2022.</div>
</li>
<li>
<div class="reference">
                  US Department of Health and Human Services (HHS); Centers for Disease Control and Prevention (CDC); National Institute for Occupational Safety and Health (NIOSH). NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href="https://www.cdc.gov/niosh/docs/2016-161/" target="_blank">https://www.cdc.gov/niosh/docs/2016-161/</a>. Updated September 2016. Accessed August 30, 2022.</div>
</li></ol></div><div id="topicVersionRevision">Topic 139348 Version 21.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
